Skip to content
value.today
Mayne Pharma Group Limited logo

Mayne Pharma Group Limited

MYX.AX
$330 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
—
annual
Net income
—
Employees
—

Mayne Pharma Group Limited in brief

Mayne Pharma Group Limited is a listed company in the Pharmaceutical industry, based in Australia. It was founded in 1845. Its last known market value was $330 M (January 2024); there is no current figure. Its shares trade under the symbol MYX.AX (ASX).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Mayne Pharma Group Limited

Mayne Pharma Group Ltd is an ASX listed specialty pharmaceutical company focused on commercializing branded and generic pharmaceuticals. The company annual revenue is 400.3 million EUR, annual operating income is 21.3 million EUR and total assets are 1,463 million EUR as on 2021. The headquarters is in Australia.

Mayne Pharma Group Limited timeline

2 events, 1845–2007
  1. 1845
  2. 🏁
    · approximate
    Founded
  3. 2007
  4. 🔔
    Initial public offering on Australian Securities Exchange as MYX

Events of Mayne Pharma Group Limited from Wikidata. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$97 M$195 M$292 M$390 M20232024

World rank over time

▲ up 336 places since 2022
2022-01-07: #15505#15,50520222022-12-25: #17450#17,45020222023-07-30: #16429#16,42920232024-01-05: #15169#15,1692024

Rank in Australia: #344 (Jan 2022) · #372 (Dec 2022) · #340 (Jul 2023) · #298 (Jan 2024)

Mutual funds holding Mayne Pharma Group Limited#

27 funds hold shares worth $6 M. Since their previous reports 7 added shares and 6 sold, selling $0 M net.
Mutual funds holding Mayne Pharma Group Limited
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total International Stock Index FundThe Vanguard Group, Inc.1.04 M$2 M—<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Developed Markets Index FundThe Vanguard Group, Inc.794,498$2 M—<0.01%no changeJun 30, 2026
🇺🇸 International Core Equity 2 PortfolioDimensional Fund Advisors LP280,148$1 M—<0.01%no changeJul 31, 2026
🇺🇸 The Asia Pacific Small Company SeriesDimensional Fund Advisors LP228,283$0 M—0.02%−24%Jul 31, 2026
🇺🇸 Vanguard Ftse All-World Ex-Us Small-Cap Index FundThe Vanguard Group, Inc.208,615$0 M—<0.01%−41%Jul 31, 2026
🇺🇸 Avantis International Small Cap Value ETFAmerican Century ETF Trust147,610$0 M—<0.01%newMay 31, 2026
🇺🇸 Vanguard Pacific Stock Index FundThe Vanguard Group, Inc.101,822$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Dimensional International Small Cap ETFDimensional Fund Advisors LP90,536$0 M—<0.01%−11%Jul 31, 2026
🇺🇸 iShares International Small-Cap Equity Factor ETFBlackRock Fund Advisors62,178$0 M—0.02%+2.1%Jul 31, 2026
🇺🇸 Dimensional International Core Equity 2 ETFDimensional Fund Advisors LP61,400$0 M—<0.01%no changeJul 31, 2026
🇺🇸 State Street SPDR S&P International Small Cap ETFSSGA Funds Management, Inc.53,582$0 M—0.01%+1.0%Jun 30, 2026
🇺🇸 Vanguard Total World Stock Index FundThe Vanguard Group, Inc.45,285$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Old Westbury Small & Mid Cap Strategies FundBessemer Investment Management LLC42,819$0 M—<0.01%newJul 31, 2026
🇺🇸 Dfa International Small Cap Value PortfolioDimensional Fund Advisors LP41,255$0 M—<0.01%newJul 31, 2026
🇺🇸 Avantis International Equity ETFAmerican Century ETF Trust42,015$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Dimensional International Core Equity Market ETFDimensional Fund Advisors LP17,302$0 M—<0.01%−45%Jul 31, 2026
🇺🇸 Brighthouse/Dimensional International Small Company PortfolioBrighthouse Investment Advisers, LLC15,480$0 M—<0.01%no changeJun 30, 2026
🇺🇸 International Vector Equity PortfolioDimensional Fund Advisors LP14,630$0 M—<0.01%−51%Jul 31, 2026
🇺🇸 Dimensional VA International Small PortfolioDimensional Fund Advisors LP14,501$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Esg International Stock ETFThe Vanguard Group, Inc.11,925$0 M—<0.01%no changeMay 31, 2026
🇺🇸 LVIP Dimensional International Core Equity FundLincoln Financial Investments Corporation10,321$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Avantis Responsible International Equity ETFAmerican Century ETF Trust7,666$0 M—<0.01%+0.9%May 31, 2026
🇺🇸 International Small Company TrustJohn Hancock Variable Trust Advisers LLC4,957$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Avantis International Small Cap Equity ETFAmerican Century ETF Trust5,498$0 M—<0.01%+18%May 31, 2026
🇺🇸 AZL DFA International Core Equity FundAllianz Investment Management LLC4,918$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Avantis International Equity FundAmerican Century ETF Trust2,120$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Dimensional International Vector Equity ETFDimensional Fund Advisors LP907$0 M—<0.01%no changeJul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 27 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

FDA drug approvals: Mayne Pharma Group Limited#

16 approved applications held, 3 of them new molecular entities; 1 approvals and 0 new uses in 2022.

Approvals held
16
New molecular entities
3
New uses approved
9
efficacy supplements
Generics
3
13 new drugs, 0 biologics
Mayne Pharma Group Limited: latest FDA approvals
ApprovedDrugKind
2022-04-22EpsolayBenzoyl Peroxide · NDA214510New drug (NDA)
2021-12-28Bijuvanew useEstradiol, Progesterone · NDA210132 (SUPPL-6)New drug (NDA)
2021-08-18Lexettenew useHalobetasol Propionate · NDA210566 (SUPPL-3)New drug (NDA)
2021-07-26TwyneoBenzoyl Peroxide, Tretinoin · NDA214902New drug (NDA)
2021-04-15Nextstellisnew moleculeDrospirenone, Estetrol · NDA214154New drug (NDA)
2019-11-05Soriluxnew useCalcipotriene · NDA022563 (SUPPL-7)New drug (NDA)
2019-05-06Soriluxnew useCalcipotriene · NDA022563 (SUPPL-6)New drug (NDA)
2018-12-11TolsuraItraconazole · NDA208901New drug (NDA)
2018-10-28BijuvaEstradiol, Progesterone · NDA210132New drug (NDA)
2018-08-10Annoveranew moleculeEthinyl Estradiol, Segesterone Acetate · NDA209627New drug (NDA)
2018-05-29ImvexxyEstradiol · NDA208564New drug (NDA)
2018-05-24LexetteHalobetasol Propionate · NDA210566New drug (NDA)
2017-05-31Doryx Mpc, Doryxnew useDoxycycline Hyclate · NDA050795 (SUPPL-24)New drug (NDA)
2017-01-18Rhofadenew moleculeOxymetazoline Hydrochloride · NDA208552New drug (NDA)
2016-05-20Doryx Mpc, Doryxnew useDoxycycline Hyclate · NDA050795 (SUPPL-22)New drug (NDA)
2015-11-17Hydrocodone Bitartrate And Pseudoephedrine HydrochlorideHydrocodone Bitartrate, Pseudoephedrine Hydrochloride · ANDA205658Generic drug (ANDA)
2015-08-03Hydrocodone Bitartrate, Chlorpheniramine Maleate And Pseudoephedrine HydrochlorideChlorpheniramine Maleate, Hydrocodone Bitartrate, Pseudoephedrine Hydrochloride · ANDA205657Generic drug (ANDA)
2013-04-11Doryx Mpc, Doryxnew useDoxycycline Hyclate · NDA050795 (SUPPL-10)New drug (NDA)
2012-09-27Soriluxnew useCalcipotriene · NDA022563 (SUPPL-2)New drug (NDA)
2012-05-11FabiorTazarotene · NDA202428New drug (NDA)
2010-10-06SoriluxCalcipotriene · NDA022563New drug (NDA)
2007-08-20Fentanyl-75, Fentanyl-25, Fentanyl-100, Fentanyl-50Fentanyl · ANDA077062Generic drug (ANDA)
2006-12-19Doryx Mpc, Doryxnew useDoxycycline Hyclate · NDA050795 (SUPPL-2)New drug (NDA)
2005-05-06Doryx Mpc, DoryxDoxycycline Hyclate · NDA050795New drug (NDA)
1985-07-22DoryxDoxycycline Hyclate · NDA050582New drug (NDA)

Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (MAYNE PHARMA), so they follow acquisitions

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
Mayne Pharma Group Limited🇦🇺$330 M———
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Profile updated:
Nov 15, 2026

Figures from Wikidata, value.today research.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Mayne Pharma Group Limited? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Mayne Pharma Group Limited's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Mayne Pharma Group Limited? Suggest a correction